Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Long-Term Deferred Tax (2020 - 2025)

China Pharma Holdings filings provide 10 years of Long-Term Deferred Tax readings, the most recent being $22.9 million for Q4 2025.

  • On a quarterly basis, Long-Term Deferred Tax rose 5.53% to $22.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.9 million, a 5.53% increase, with the full-year FY2025 number at $22.9 million, up 5.53% from a year prior.
  • Long-Term Deferred Tax hit $22.9 million in Q4 2025 for China Pharma Holdings, up from $22.7 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $24.0 million in Q4 2021 to a low of $21.5 million in Q4 2023.
  • Median Long-Term Deferred Tax over the past 5 years was $22.0 million (2022), compared with a mean of $22.4 million.
  • Biggest five-year swings in Long-Term Deferred Tax: decreased 13.32% in 2021 and later rose 5.53% in 2025.
  • China Pharma Holdings' Long-Term Deferred Tax stood at $24.0 million in 2021, then fell by 8.33% to $22.0 million in 2022, then dropped by 2.07% to $21.5 million in 2023, then rose by 0.78% to $21.7 million in 2024, then rose by 5.53% to $22.9 million in 2025.
  • The last three reported values for Long-Term Deferred Tax were $22.9 million (Q4 2025), $22.7 million (Q3 2025), and $22.1 million (Q2 2025) per Business Quant data.